Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphomaWyndham H. Wilson, Louis M. Staudt, Vaishalee P. Kenkre et al.|Nature Medicine|2015Cited by 1.1k
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphomaJaroslav Žák, John R. Teijaro, Isaraphorn Pratumchai et al.|Science|2024Cited by 173
Allogeneic transplant following CAR T-cell therapy for large B-cell lymphomaJoanna Zurko, Alex F. Herrera, Jeremy Ramdial et al.|Haematologica|2022Cited by 73
Long-term Follow-up of Patients with Relapsed or Refractory Non–Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human StudyMatthew S. Davids, John F. Seymour, Andrew W. Roberts et al.|Clinical Cancer Research|2021Cited by 69
Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHLJoanna Zurko, Reem Karmali, Imran Nizamuddin et al.|Blood Advances|2022Cited by 50